OVERSEA CHINESE BANKING Corp Ltd Has $1.84 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

OVERSEA CHINESE BANKING Corp Ltd raised its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 1,123.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,845 shares of the company's stock after acquiring an additional 26,488 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd's holdings in Moderna were worth $1,844,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Intrinsic Value Partners LLC lifted its stake in Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company's stock valued at $3,435,000 after purchasing an additional 24,505 shares during the last quarter. Vontobel Holding Ltd. lifted its position in shares of Moderna by 148.2% during the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company's stock valued at $7,758,000 after acquiring an additional 69,313 shares during the last quarter. Profund Advisors LLC boosted its stake in shares of Moderna by 20.9% during the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company's stock worth $6,676,000 after acquiring an additional 9,719 shares in the last quarter. Privium Fund Management B.V. grew its holdings in shares of Moderna by 74.0% in the 3rd quarter. Privium Fund Management B.V. now owns 40,482 shares of the company's stock worth $2,705,000 after acquiring an additional 17,221 shares during the last quarter. Finally, Tobam raised its position in shares of Moderna by 121.6% during the third quarter. Tobam now owns 27,794 shares of the company's stock worth $1,857,000 after purchasing an additional 15,249 shares during the period. Institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Moderna stock traded down $1.33 during mid-day trading on Wednesday, hitting $42.14. 7,703,135 shares of the company's stock were exchanged, compared to its average volume of 4,583,898. Moderna, Inc. has a 1-year low of $41.54 and a 1-year high of $170.47. The stock has a 50 day moving average of $61.15 and a two-hundred day moving average of $98.65. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm's revenue was up 3.8% compared to the same quarter last year. During the same period last year, the business earned ($1.39) EPS. On average, equities analysts expect that Moderna, Inc. will post -9.34 EPS for the current year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO James M. Mock sold 715 shares of the company's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company's stock, valued at $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. The Goldman Sachs Group dropped their price target on Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a "sell" rating to a "hold" rating and reduced their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Jefferies Financial Group lowered their price objective on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research report on Tuesday, October 15th. HSBC upgraded Moderna from a "reduce" rating to a "hold" rating and set a $82.00 target price for the company in a report on Wednesday, August 28th. Finally, Oppenheimer downgraded Moderna from an "outperform" rating to a "market perform" rating in a report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Moderna has a consensus rating of "Hold" and a consensus price target of $93.18.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.